메뉴 건너뛰기




Volumn 13, Issue 4, 2009, Pages 400-402

Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BEVACIZUMAB; C REACTIVE PROTEIN; CARBONATE DEHYDRATASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; DNA ANTIBODY; DORZOLAMIDE; FOLIC ACID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; STEROID; TIMOLOL;

EID: 68349092786     PISSN: 10918531     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaapos.2009.03.006     Document Type: Article
Times cited : (52)

References (10)
  • 1
    • 45449108608 scopus 로고    scopus 로고
    • Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease
    • Cakir M., Cekiç O., and Yilmaz O.F. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS 1 (2008) 309-311
    • (2008) J AAPOS , vol.1 , pp. 309-311
    • Cakir, M.1    Cekiç, O.2    Yilmaz, O.F.3
  • 2
    • 60249086822 scopus 로고    scopus 로고
    • Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease
    • Cakir M., Cekiç O., and Yilmaz O.F. Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease. J AAPOS 13 (2009) 94-96
    • (2009) J AAPOS , vol.13 , pp. 94-96
    • Cakir, M.1    Cekiç, O.2    Yilmaz, O.F.3
  • 4
    • 33750305221 scopus 로고    scopus 로고
    • Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study
    • Moshfeghi A.A., Rosenfeld P.J., Puliafito C.A., Michels S., Marcus E.N., Lenchus J.D., and Venkatraman A.S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113 (2006) 2002.e1-2002.e12
    • (2006) Ophthalmology , vol.113
    • Moshfeghi, A.A.1    Rosenfeld, P.J.2    Puliafito, C.A.3    Michels, S.4    Marcus, E.N.5    Lenchus, J.D.6    Venkatraman, A.S.7
  • 7
    • 61549094645 scopus 로고    scopus 로고
    • The effect of unilateral intravitreal bevacizumab (Avastin), in the treatment of diffuse bilateral diabetic macular edema: A pilot study
    • Velez-Montoya R., Fromow-Guerra J., Burgos O., Landers III M.B., Morales-Catón V., and Quiroz-Mercado H. The effect of unilateral intravitreal bevacizumab (Avastin), in the treatment of diffuse bilateral diabetic macular edema: A pilot study. Retina 29 (2009) 20-26
    • (2009) Retina , vol.29 , pp. 20-26
    • Velez-Montoya, R.1    Fromow-Guerra, J.2    Burgos, O.3    Landers III, M.B.4    Morales-Catón, V.5    Quiroz-Mercado, H.6
  • 8
    • 38449109935 scopus 로고    scopus 로고
    • Inflammatory cystoid macular edema
    • Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol 18 (2007) 487-492
    • (2007) Curr Opin Ophthalmol , vol.18 , pp. 487-492
    • Rothova, A.1
  • 10
    • 38049123471 scopus 로고    scopus 로고
    • Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: A pilot study
    • Mackensen F., Heinz C., Becker M.D., and Heiligenhaus A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: A pilot study. Retina 28 (2008) 41-45
    • (2008) Retina , vol.28 , pp. 41-45
    • Mackensen, F.1    Heinz, C.2    Becker, M.D.3    Heiligenhaus, A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.